In pre-clinical models, the β3-AR agonists attenuated cardiac hypertrophy and fibrosis and improved cardiac contractility via coupling of β3-AR to the eNOS/cGMP pathway and activating Na+/K+-ATPase-mediated Na+ export in the cardiomyocytes. The gene discussed is NOS3; the disease is cardiac hypertrophy.